RxDoctor Payments DataLook up a doctor →

Frank Navetta, MD

Interventional Cardiology · Tyler, TXNPI 1811982986

Payments from drug & device makers

$1,396,759in general payments, 2019–2025

Across 365 payments — averaging $3826.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1.4M
  • Novartis$1K
  • Amgen$948
  • Boston Scientific$315
  • Johnson & Johnson$251
  • Amarin Pharma, Inc.$170
  • plus $1K from 25 others

What the payments were for

  • Consulting fees$400%
  • Speaking & faculty fees$24,82577%
  • Travel & lodging$1,9936%
  • Food & beverage$5,36917%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,396,759 in reported general payments places this provider in the 95th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$398,785
Medicare patients
1,740
Services billed
7,376

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban253$264,111
XareltoRivaroxaban130$120,699
EntrestoSacubitril/Valsartan81$88,792
Repatha SureclickEvolocumab71$44,217
JardianceEmpagliflozin59$40,547
BrilintaTicagrelor16$14,373
Praluent PenAlirocumab26$13,422
MultaqDronedarone Hcl12$8,926
Metoprolol Succinate209$3,940
LivaloPitavastatin Calcium12$3,865
Ezetimibe169$3,578
Isosorbide Mononitrate ErIsosorbide Mononitrate272$3,535
Potassium Chloride155$3,496
Carvedilol281$3,346
ClopidogrelClopidogrel Bisulfate274$3,320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$58$264,111253 claims
Johnson & JohnsonXarelto$251$120,699130 claims
NovartisEntresto$1,402$88,79281 claims
Boehringer IngelheimJardiance$33$40,54759 claims
AstraZenecaBrilinta$94$14,37316 claims
Sanofi-aventis U.S. LLCMultaq$49$8,92612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →